Metabolism of dynorphin A1–13 in human CSF

Abstract

In-vitro incubation of human cerebrospinal fluid (CSF) obtained from patients ranging from 22–78 years with 10 μM of dynorphin A1–13 (Dyn A1–13) resulted in several cleavage products. Dyn A1–12 and A2–13 were identified as the major CSF metabolites by matrix-assisted laser desorption mass spectrometry (LD-MS). Further metabolites were Dyn A1–6, A2–12 and A4–12. LD-MS further suggested the formation of Dyn A1–8, A1–7, A1–10, A7–10, A3–12, A7–12, A3–13, A7–13 and A8–13. The metabolic half-life of Dyn A1–13 at 37°C was approximately 2.5 h (range 1.75–8.5 h), compared to less than one minute in plasma. The half-life of Dyn A1–13 decreased markedly with age or age-associated processes (n=20, r²=0.498). Noncompartmental kinetic analysis in the absence or presence of enzyme inhibitors (leucinethiol 10 μM, captopril 100 μM and GEMSA 20 μM) suggested that Dyn A1–13 is mainly metabolized by carboxypeptidase to A1–12 (51%) and by aminopeptidases to A2–13 (35%). The generation of A1–6 (13%) was only detected under enzyme inhibition. The extent of conversion into the main metabolites did not follow an age-associated trend, thus over-all enzyme levels but no specific enzymatic systems are elevated with age.